Filovirus
Read More about this categoryShow Less
Filoviruses is amongst the most lethal of primate pathogens. Filoviruses cause lethal hemorrhagic fever in humans and nonhuman primates. The family Filoviridae includes two genera: Marburgvirus, comprising various strains of the Lake Victoria marburgvirus (MARV); and Ebolavirus (EBOVs), comprising four species including Sudan ebolavirus (SEBOV), Zaire ebolavirus (ZEBOV), Ivory Coast ebolavirus (CIEBOV), and Reston ebolavirus (REBOV); and a tentative species Bundibugyo ebolavirus (BEBOV).
The infections typically affect multiple organs in the body and are often accompanied by hemorrhage (bleeding). Once the virus has been transmitted from an animal host to a human, it can then spread through person-to-person contact.
Products Related to Filovirus(14)
- GC32089Galidesivir hydrochloride (BCX 4430 (hydrochloride))CAS: 222631-44-9Purity: >99.50%
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity.
- GC32092Galidesivir (BCX 4430)CAS: 249503-25-1Purity: >98.00%
Galidesivir (BCX 4430) (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity.
- GC676272'-Deoxy-5'-O-DMT-2'-fluorouridineCAS: 146954-74-7Purity: >98%
2'-Deoxy-5'-O-DMT-2'-fluorouridine, a nucleoside analogue, is a 5'-O-DMTr-5-FUDR derivative with potent anti-yellow fever (YFV) activity.
- GC72370AtoltivimabCAS: 2135632-29-8Purity: >98.00%
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
- GC72421LarcaviximabCAS: 1792982-56-9Purity: >96.00%
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
- GC72425MaftivimabCAS: 2135632-36-7Purity: >96.00%
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent.
- GC72434OdesivimabCAS: 2135632-30-1Purity: >99.00%
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein.
- GC72436PorgaviximabCAS: 1792982-55-8Purity: 98.00%
Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
- GC72446CosfroviximabCAS: 1792982-57-0Purity: 95.00%
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP).
- GC78875Antiviral agent 75CAS: 314035-79-5Purity: >98.00%
Antiviral agent 75 (example D26) is a Ebolavirus ( EBOV ) and Bundibugyo ebolavirus (BDBV) inhibitor with IC 50 s of 0.11 μM and 0.75 μM, respectively.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC14314 | Aloperine | 56293-29-9 | >98.00% | |
An alkaloid | ||||
| GC32089 | Galidesivir hydrochloride (BCX 4430 (hydrochloride)) | 222631-44-9 | >99.50% | |
Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. | ||||
| GC32092 | Galidesivir (BCX 4430) | 249503-25-1 | >98.00% | |
Galidesivir (BCX 4430) (BCX4430), an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. | ||||
| GC43228 | Cephaeline | 483-17-0 | >98.00% | |
Cephaeline is an alkaloid originally isolated from C. | ||||
| GC67627 | 2'-Deoxy-5'-O-DMT-2'-fluorouridine | 146954-74-7 | >98% | |
2'-Deoxy-5'-O-DMT-2'-fluorouridine, a nucleoside analogue, is a 5'-O-DMTr-5-FUDR derivative with potent anti-yellow fever (YFV) activity. | ||||
| GC72368 | Ansuvimab | 2375952-29-5 | >99.00% | |
Ansuvimab (Ansuvimab-zyk) is a recombinant human monoclonal IgG1 antibody that exhibits antiviral activity against Zaire ebolavirus. | ||||
| GC72370 | Atoltivimab | 2135632-29-8 | >98.00% | |
Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection. | ||||
| GC72421 | Larcaviximab | 1792982-56-9 | >96.00% | |
Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody. | ||||
| GC72425 | Maftivimab | 2135632-36-7 | >96.00% | |
Maftivimab (REGN3470-3471-3479), the inhibitor of Filovirus, is an Food and agent Administration (FDA)-approved agent. | ||||
| GC72434 | Odesivimab | 2135632-30-1 | >99.00% | |
Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. | ||||
| GC72436 | Porgaviximab | 1792982-55-8 | 98.00% | |
Porgaviximab is a monoclonal antibody that can be used Ebola infection research. | ||||
| GC72446 | Cosfroviximab | 1792982-57-0 | 95.00% | |
Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP). | ||||
| GC72667 | EBOV-IN-1 | 1335113-30-8 | >97.00% | |
EBOV-IN-1 (com 3.47) is an adamantane dipeptide piperazine and an inhibitor of Ebola virus (EBOV). | ||||
| GC78875 | Antiviral agent 75 | 314035-79-5 | >98.00% | |
Antiviral agent 75 (example D26) is a Ebolavirus ( EBOV ) and Bundibugyo ebolavirus (BDBV) inhibitor with IC 50 s of 0.11 μM and 0.75 μM, respectively. | ||||
